Dr. Merle Lindy Wade Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 Fax: 256-492-4017 |
Dr. Doyle Dawon Stephens, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 Fax: 256-492-4017 |
Dr. Lauren Nash Hendrix, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 Fax: 256-492-4017 |
Michael Jennings, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 |
George Phillips Walker, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 100 Medical Center Dr, Suite 202, Gadsden, AL 35903 Phone: 256-494-3000 Fax: 256-494-3015 |
Dr. Manish Shah, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 Fax: 256-492-4017 |
Dr. Marilyn Kelleher, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 Fax: 256-492-4017 |
Dr. John Frances Pirani, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 713 Goodyear Ave, Gadsden, AL 35903 Phone: 256-492-4040 Fax: 256-492-4017 |
News Archive
Black, Hispanic, and Native Americans constitute one-third of the U.S. population, but only 9% of practicing physicians. To address the lack of diversity and inclusion in medicine, Yale physicians conducted a study exploring the role of race and ethnicity in minority resident training experiences.
Secretary of Health and Human Services Kathleen Sebelius made her third trip to Florida in a week to tout the health law, while state officials are taking steps to stymie enrollment in the new online insurance exchanges which open in two weeks.
Surviving cancer may also mean surviving pain, according to a study by the University of Michigan Health System showing 20 percent of cancer survivors at least two years post diagnosis have current cancer-related chronic pain.
Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.
York University researchers have learned how living beings can keep gene expression in check - which might partly explain the uncontrolled gene expression found in many cancers.
› Verified 8 days ago